StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly tyvyt (sintilimab) — U.S. revenue ($M) [legacy] ($M)

Quarterly figures from Eli Lilly's filings and investor materials

QuarterlyAnnual
Latest, Q4 2024
0
Period ended Dec 31, 2024
Change on a year earlier
–
0 in Q4 2023
History
20 quarters
Since Q1 2020
Sources
12
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTyvyt (sintilimab) — U.S. revenue ($M) [legacy] ($M)Year on yearSource
Q4 2024Dec 31, 20240–Form 10-K (filed 2025-02-19) ↗
Q3 2024Sep 30, 20240–Form 10-Q (filed 2024-10-30) ↗
Q2 2024Jun 30, 20240–Form 10-Q (filed 2024-08-08) ↗
Q1 2024Mar 31, 20240–Form 10-Q (filed 2024-04-30) ↗
Q4 2023Dec 31, 20230–Form 10-K (filed 2025-02-19) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 20220–Form 10-K (filed 2025-02-19) ↗
Q3 2022Sep 30, 20220–Form 10-Q (filed 2022-11-01) ↗
Q2 2022Jun 30, 20220–Form 10-Q (filed 2022-08-04) ↗
Q1 2022Mar 31, 20220–Form 10-Q (filed 2022-04-29) ↗
Q4 2021Dec 31, 20210–Form 10-K (filed 2024-02-21) ↗
Q3 2021Sep 30, 20210–Form 10-Q (filed 2022-11-01) ↗
Q2 2021Jun 30, 20210–Form 10-Q (filed 2022-08-04) ↗
Q1 2021Mar 31, 20210–Form 10-Q (filed 2022-04-29) ↗

Cite this data

StockData. (2026). Eli Lilly Tyvyt (sintilimab) — U.S. revenue ($M) [legacy] ($M), quarterly Q1 2020–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_tyvyt_us

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.